Bellicum Pharmaceuticals (NASDAQ:BLCM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, January 12th.
According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “
Several other research firms have also weighed in on BLCM. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. BidaskClub lowered Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Finally, Jefferies Group restated a “buy” rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Bellicum Pharmaceuticals has an average rating of “Hold” and an average price target of $15.43.
Bellicum Pharmaceuticals (NASDAQ:BLCM) traded up $0.05 on Friday, hitting $5.61. The stock had a trading volume of 934,423 shares, compared to its average volume of 951,110. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals has a 52-week low of $5.02 and a 52-week high of $15.55. The stock has a market capitalization of $186.40, a PE ratio of -1.88 and a beta of 0.70.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period last year, the firm posted ($0.66) earnings per share. Bellicum Pharmaceuticals’s quarterly revenue was up 18.2% on a year-over-year basis. analysts forecast that Bellicum Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total value of $2,248,978.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $9.33, for a total value of $159,701.61. Following the completion of the sale, the chief financial officer now directly owns 31,585 shares in the company, valued at $294,688.05. The disclosure for this sale can be found here. Insiders sold 1,165,145 shares of company stock worth $9,696,662 over the last three months. Corporate insiders own 18.77% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC bought a new stake in Bellicum Pharmaceuticals in the second quarter worth $132,000. Commonwealth Equity Services Inc bought a new stake in Bellicum Pharmaceuticals in the third quarter worth $142,000. Cubist Systematic Strategies LLC bought a new stake in Bellicum Pharmaceuticals in the third quarter worth $164,000. Nationwide Fund Advisors boosted its holdings in Bellicum Pharmaceuticals by 30.4% in the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 3,620 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Bellicum Pharmaceuticals in the third quarter worth $189,000. 55.24% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/05/bellicum-pharmaceuticals-blcm-rating-lowered-to-hold-at-zacks-investment-research.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.